chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Acute Bronchitis 7 days after first shot; Sore throat 7 days after first shot; Laryngitis 7 days after first shot; Severe allergic reaction to the first shot; Vomiting 7 days after first shot; Headache 6 hours after first shot; Achy body  6 hours after first shot  6 hours after first shot; Felt tired 6 hours after first shot; Tight chest  6 hours after first shot; Felt weak 6 hours after first shot; This spontaneous case was reported by a consumer and describes the occurrence of BRONCHITIS (Acute Bronchitis 7 days after first shot), OROPHARYNGEAL PAIN (Sore throat 7 days after first shot), LARYNGITIS (Laryngitis 7 days after first shot), CHEST DISCOMFORT (Tight chest  6 hours after first shot) and ASTHENIA (Felt weak 6 hours after first shot) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Collapse of lung (Collapsed lung 1980 & 1982) in 1980 and Splenectomy in 1996.    On 24-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Apr-2021, the patient experienced CHEST DISCOMFORT (Tight chest  6 hours after first shot), ASTHENIA (Felt weak 6 hours after first shot), HEADACHE (Headache 6 hours after first shot), MYALGIA (Achy body  6 hours after first shot  6 hours after first shot) and FATIGUE (Felt tired 6 hours after first shot). On 02-May-2021, the patient experienced BRONCHITIS (Acute Bronchitis 7 days after first shot), OROPHARYNGEAL PAIN (Sore throat 7 days after first shot), LARYNGITIS (Laryngitis 7 days after first shot), HYPERSENSITIVITY (Severe allergic reaction to the first shot) and VOMITING (Vomiting 7 days after first shot). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) at an unspecified dose and frequency. On 24-May-2021, BRONCHITIS (Acute Bronchitis 7 days after first shot), OROPHARYNGEAL PAIN (Sore throat 7 days after first shot), LARYNGITIS (Laryngitis 7 days after first shot), CHEST DISCOMFORT (Tight chest  6 hours after first shot), ASTHENIA (Felt weak 6 hours after first shot), HYPERSENSITIVITY (Severe allergic reaction to the first shot), VOMITING (Vomiting 7 days after first shot), HEADACHE (Headache 6 hours after first shot), MYALGIA (Achy body  6 hours after first shot  6 hours after first shot) and FATIGUE (Felt tired 6 hours after first shot) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication were reported  Medical History included Lung surgery 1982.  Patient visited the urgent care 3 times after the first vaccine. Patient had negative COVID, Patient never had COVID disease. Patient had a disrupted raspatory system for 1 month after the first shot. Patient took Steroid injection, and Nebulizer treatment. patient was 4 weeks to feel normal. patient didn't took  second shot, because patient had  severe allergic reaction to the first shot.
I am experiencing ringing in my ears or head which started mid year 2021.   I was a perfectly healthy adult.   Never drank liquor,  never smoked, or did any drugs.   Now I am not only experiencing ringing, I am getting slight headaches and dizziness which cause my blood pressure to spike extremely high and then drop to almost normal (strange).   I have lost my job due to this conditions. I am lucky to have found another job and if I can't perform, I will lose this job too.   The sound in my ear makes it so difficult to concentrate and the dizziness unbearable to function.  I started to experience these issues after I took the second covid vaccine. I am hoping that this annoyance will someday go away. I have see an ENT and my hearing is ok.   I am now seeing a neurologist and getting an MRI follow by a cardiologist.
Fever on the next day of 100.2; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 04May2021 at 10:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take any concomitant medications. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 20Apr2021 at 10:00 (at the age of 41-years-old), as a single dose for COVID-19 immunisation. On 05May2021 at 06:00, the patient experienced fever on the next day of 100.2 (unspecified units) and fatigue; lasted 24 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. No therapeutic measures were taken as a result of the reported events. The clinical outcome of events fever on the next day of 100.2 and fatigue were recovered on 06May2021 at 06:00, after the duration of 24 hours.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
administer the vaccine after 12 hours after first puncturing.; No adverse event; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administer the vaccine after 12 hours after first puncturing.) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (administer the vaccine after 12 hours after first puncturing.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administer the vaccine after 12 hours after first puncturing.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (administer the vaccine after 12 hours after first puncturing.).    No concomitant medication was reported. Patient was administered with the vaccine after 12 hours after first puncturing. No treatment information was reported.
2nd set of Reaction.  Hives broke out all over body, looks like Mumps.  traveled to face, around eyes.
soreness of arm (not as severe as 1st dose); severe chills & fever of 101.7°f; severe headache; extreme fatigue the next day.; severe chills & fever of 101.7°f; severe headache; extreme fatigue the next day; severe headache; extreme fatigue the next day; severe headache; extreme fatigue the next day; This is a spontaneous report from a contactable consumer (Patient) via COVID-19 Self-Reporting. A 51-years-old female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Lot Number: EP8734), via an unspecified route of administration, administered in right arm on 07Apr2021 at 10:15 AM (at the age of 51-year-old) as DOSE 2, SINGLE for COVID-19 immunisation at pharmacy. The patient medical history included ongoing breast cancer-dx from 2019 and ongoing treatment with aromatase inhibitor for it, Covid-19 (prior to vaccination) from an unknown date and unknown if ongoing. The patient previously took ciprofloxacin and experienced drug hypersensitivity, Known allergies to cipro antibiotic. Historical Vaccine include bnt162b2 (BNT162B2, Formulation: Solution for injection, Lot number: EP7534) via an unspecified route of administration, administered in right arm on 17Mar2021 at 10:15 AM (at the age of 51-year-old) as dose 1 single for COVID-19 immunisation and experienced severe soreness of arm where injected (could not lift arm up for several hours), and experienced mild fever (100°F). The patient concomitant medication(s) (other medications in two weeks) included ARIMIDEX, CALCIUM, and VITAMIN D. The patient did not received any other vaccine in four weeks. There is no COVID tested post vaccination. On 08Apr2021 at 01:30 15 hours 15 minutes after the second dose, the patient experienced soreness of arm (not as severe as 1st dose), severe chills, & fever of 101.7 Fahrenheit. Started, severe headache and extreme fatigue the next day. The patient underwent lab tests and procedures which included on 08Apr2021, body temperature 101.7 Fahrenheit. Treatment not received for the events. Outcome of the events was resolved on an unspecified date in 2021.  No follow up attempts are possible. Information about lot/batch number cannot be obtained.
Woke up with really strong heart palpitations that went on for almost 2 days and then faded slowly over one week. So strong that they woke me up several times and were quite intense.
Soreness in the arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  An elderly male patient received bnt162b2 (BNT162B2), as dose 4 (booster), single (Lot number: FJ4895) for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (dose 1, lot number:EK4176), for COVID-19 immunisation, reaction(s): "Soreness in the arm"; Bnt162b2 (dose 2, lot number:EL9261), for COVID-19 immunisation, reaction(s): "Soreness in the arm"; Bnt162b2 (dose 3), for COVID-19 immunisation, reaction(s): "Soreness in the arm". The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "Soreness in the arm".  Additional information: lot number was reported as "FJ4895 or 85".; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300367340 same patient, different vaccine dose number/different event;
ONCE VACCINE WAS ADMINISTERED, THE PATIENT IMMEDIATELY STATED THAT HE FELT DIZZY. SKIN WAS CLAMMY, PULSE WAS ELEVATED. HE FELT LIGHTHEADED AND HE DESCRIBED HIS VISION AS "WHITE". I GAVE HIM AN ICE PACK, AND THEN WAS PREPARING TO LAY HIM ON THE GROUND. HE PASSED OUT, BUT DID NOT FALL AS WE LEANED HIM BACKWARD IN THE CHAIR.HE WAS UNCONSCIOUS FOR  ABOUT 30 SECONDS. HE THEN BEGAN TO REGAIN CONSIOUSNESS AND WAS RESPONSIVE AND ANSWERED QUESTIONS APPROPRIATELY. WE GAVE HIM ORANGE JUICE AND BOTTLED WATER AND OBSERVED HIM FOR 40 MINUTES. HE REFUSED MEDICAL TRANSPORT, BUT REMAINED IN THE VICINITY FOR ABOUT 30 MINUTES LONGER. PULSE RETURNED TO 78bpm, AND COLOR WAS NORMAL BEFORE PATIENT LEFT THE PHARMAC AREA.
Patient received 5 year old immunizations on 4/21/04. Patient received DTaP only in left arm. Patient was seen on 4/23/04 for cellulitis left arm and was prescribed antibiotic course. Nurse follow up on 05/18/04 states: ADD: MMR # 2, Merck, Lot # 0138N, RA; IPV # 4, Aventis, Lot # W0334, RA.
covid vaccine breakthrough case  dose 1 Pfizer 2/25/21 EN6198 dose 2 Pfizer 3/18/21 EN6205 dose 3 Pfizer 10/24/21 FH8020
devel erythema papules chest, abd 30JUN98 total 30-40 lesions;scattered papules vesicles legs, upper thighs;
Arm pain at site; This is a spontaneous report from a contactable nurse.  A 59-year-old female patient received bnt162b2 (lot number: EH9899), intramuscular on right arm from 16Dec2020 15:45, at an unspecified dose, single, for immunization.  Medical history included hypertension. The patient's concomitant medications were not reported. Patient had other medications the patient received within 2 weeks of vaccination. On 16Dec2020 at 19:45, the patient experienced arm pain at site. Outcome of event was unknown.  Event occurred in a country different from that of the reporter.  This may be a duplicate if the reporter also submitted directly to his/her local agency.
marble sized swelling in his armpit; swollen lymph nodes under the armpit/swollen lymph nodes under the armpit/swollen lymph nodes under the arm pit was worsened; marble sized swelling in his armpit that was painful; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team.  A 35 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 24Jan2022 14:00 (Lot number: 33130BA) at the age of 35 years as dose 3 (booster), single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Bnt162b2 (Dose 1 , Lot: EW0186, Expiration: unknown), administration date: 23Jun2021, when the patient was 34 years old, for Covid-19 Immunization, reaction(s): "he had stage one kidney disease."; Bnt162b2 (Dose 2, Lot: EW0186 (confirms both doses are the same lot number. , Expiration: unknown), administration date: 14Jul2021, when the patient was 34 years old, for Covid-19 Immunization, reaction(s): "he had stage two kidney disease".  The following information was reported: SWELLING (non-serious) with onset 24Jan2022 19:00, outcome "not recovered", described as "marble sized swelling in his armpit"; LYMPHADENOPATHY (non-serious) with onset 24Jan2022 19:00, outcome "not recovered", described as "swollen lymph nodes under the armpit/swollen lymph nodes under the armpit/swollen lymph nodes under the arm pit was worsened"; AXILLARY PAIN (non-serious) with onset 24Jan2022 19:00, outcome "unknown", described as "marble sized swelling in his armpit that was painful". The events "marble sized swelling in his armpit", "swollen lymph nodes under the armpit/swollen lymph nodes under the armpit/swollen lymph nodes under the arm pit was worsened" and "marble sized swelling in his armpit that was painful" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of swelling, lymphadenopathy.  Additional information: As of 27Jan2022, it was "3/4 the size of a baseball" and the patient had to keep his arm raised/can't lower his arm all the way because of it. She wants to know if have information on swollen lymph nodes after the vaccine. The patient not received any other product. It was stated that Her partner also had swollen lymph nodes under the arm pit. She just does not know if it supposed to get that large under his armpit. The swelling underneath his arm pit was larger than her fist. No any additional vaccines administered on same date of the Pfizer suspect. The events did not cause Emergency Room visit. No any prior vaccination within 4 weeks. No any family medical history relevant to events. The patient was Advised to consult with HCP.  Follow-up attempts are completed. No further information is expected.
Shivers/shaking in the beginning, developed into full body chills (violent shivers) and all over body pain. This lasted for about an entire day, full body excruciating pain with constant chills/sweating.
LYMPH NODE IN LEFT ARM ON THE PATH OF THE LYPHATIC VESSEL IS RED SWOLLEN AND PAINFUL. ( ABOUT 2 INCHES IN DIAMETER)  NOT SEVERE BUT NOTICEALBE
Flu like symptoms with low grade fever, sinus congestion, myalgias and fatigue lasting for at least 12 days.
There were no product quality complaints or additional adverse events reported in this case; an adult patient who inadvertently received a 0.5 mL pediatric dose of RECOMBIVAX for his final dose in the series; The patient should have received the adult dose, 1.0mL; This spontaneous report was received from a Registered Nurse, referring to an adult male patient of unknown age. Information regarding the patient's pertinent medical history, concurrent conditions, concomitant therapies, and previous drug reactions or allergies was not provided.  On 31-MAR-2021, the patient was vaccinated with hepatitis b vaccine (recombinant) (RECOMBIVAX HB) for prophylaxis (formulation, route of administration, vaccination scheme frequency, and anatomical location were not reported; lot number and expiration date were unknown by the reporter), however, inadvertently the patient received a 0. 5 milliliter (mL) pediatric dose of hepatitis b vaccine (recombinant) (RECOMBIVAX HB) for his final dose in the series, which was outside of the recommended dose in the prescribing information (product administered to patient of inappropriate age). The reported stated that the patient should had received the adult dose (1.0 mL) (incorrect dose administered) and wanted to know if patient should be re-vaccinated. No adverse events were reported.
I have had pain in my left arm since date of injection. At first it was just sore & then within days, I had pain lifting my arm.  I?ve also had a burning sensation in upper arm  &  just a general soreness.  I saw my  primary physician & she referred me for physical therapy (I have not done that yet) and also referred me to an orthopedic doctor. I am waiting for them to contact me for an appointment.
Headache, Myalgia, fatigue, swollem, red itchy site 24 hrs Narrative:  Other Relevant History:
Sore arm started immediately. Chills, body aches started 24 hours after injection. Lasted all night but was better in morning.
I21.4 ACUTE NON ST ELEVATION MI 11/29/2022 ACUTE NON ST ELEVATION MI I21.4 ACUTE NON ST ELEVATION MI 11/29/2022 ACUTE NON ST ELEVATION MI CAD W ANGINA AND SPASM
Within 5 hours of the injection, I had extreme head to toe joint pain. I had never experienced anything like it before. The pain lasted through the night. Next morning abdominal cramps and diarrhea. That lasted about 6 hours.
pt recv vax JUN95 & AUG95 & lab eval revealed a loss of seroconversion in NOV97;
This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 46 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date 08Apr2021 (Lot number: EW0150) at the age of 46 years as dose 2, single for Covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: LOSARTAN; HCTZ. Vaccination history included: Bnt162b2 (I received my 1st COVID vaccine), administration date: 18Mar2021, when the patient was 46 years old, for Covid-19 immunization, reaction(s): "itching is worse at my injection sites". The following information was reported: FEELING ABNORMAL (non-serious) with onset 08Apr2021, outcome "not recovered", described as "Brain fogginess"; PRURITUS (non-serious) with onset 08Apr2021, outcome "not recovered", described as "itchy skin/itching is worse at my injection sites (right and left deltoids)". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of feeling abnormal, pruritus. Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. No follow-up attempts are possible. No further information is expected.
Fatigue started 2 days after the shot.  In another day or two, I got a fever.  The fever was intermittent throughout the day, but I had a fever every day from  09/27/20 - 10/13/20.   (Part of that time, from 10/10/20 -10/17/20, I was hospitalized and receiving antibiotics.)
the patient had "titers drawn on anunspecified date which showed low titers for Mumps."; improperly stored MMR II; This spontaneous report has been received from a nurse, referring to a currently 44 years old female patient. The patient had no pertinent medical history, concomitant medication nor drug reactions or allergies.    On an unknown date (reported when the patient was a child), the patient was vaccinated with an unspecified measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) (strength, lot# and expiration date were unknown) intramuscularly for prophylaxis (reported as routine vaccination). On an unspecified date, the patient had  titers drawn which showed low for mumps. It was reported that the patient sought medical attention and the patient went to the physician office, then on 18-NOV-2019, the patient was vaccinated with a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (lot# S007813, expiration date 14-MAR-2021, strength was unknown) intramuscularly for prophylaxis (reported as routine vaccination). On 19-DEC-2019, the patient was vaccinated with a booster dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (lot# S007813, expiration date 14-MAR-2021, strength was unknown) intramuscularly for prophylaxis (reported as routine vaccination), following a temperature excursion. Properly stored sterile diluent (STERILE DILUENT) (lot# S016837, expiration date 01-FEB-2022) was used to reconstitute both the initial dose and the improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II). The outcome of titers drawn which showed low for mumps was unknown, the causality between measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (manufacturer unknown) and the event was not reported, the causality between measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) and the event was not related.  The vaccine was exposed to temperature excursion of above 9 degrees Celsius (17 C) for 71 hours. No previous temperature excursion. The call was due to a data logger. No product quality complaint presented.
No other AE; Improper storage of product in use; This spontaneous report was received from medical assistant and refers to a 4-year-old patient of unknown gender. The patient's medical history and concurrent conditions were not reported. Concomitant medications included sterile diluent.  On 05-JUN-2023, the patient was vaccinated with improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) injection, unk, lot #W024971, expiration date: 05-FEB-2024, administered for prophylaxis (anatomical location , and route of administration were not provided) (product storage error). Administrated measles, mumps, rubella and varicella (oka-merck) virus vaccine live recombinant Human albumin (rHA) (PROQUAD) was stored at 12.45 Fahrenheit degrees (F) for 20 minutes, previous temperature excursion were reported: 42.31 F for 36 hours and 35 minutes.  There were no adverse events reported (no adverse event).  This is one of several reports received from the same reporter.